{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:15:33Z","timestamp":1789676133105,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,21]],"date-time":"2015-02-21T00:00:00Z","timestamp":1424476800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s13318-015-0266-5","type":"journal-article","created":{"date-parts":[[2015,2,20]],"date-time":"2015-02-20T11:59:59Z","timestamp":1424433599000},"page":"345-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy"],"prefix":"10.1007","volume":"41","author":[{"given":"Yunli","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengzhe","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,21]]},"reference":[{"issue":"11","key":"266_CR1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/bmc.858","volume":"21","author":"G Alves","year":"2007","unstructured":"Alves G, Figueiredo I, Castel-Branco M, Loureiro A, Fortuna A, Falc\u00e3o A, Caramona M (2007) Enantioselective HPLC\u2013UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. Biomed Chromatogr 21(11):1127\u20131134","journal-title":"Biomed Chromatogr"},{"issue":"1","key":"266_CR2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40262-013-0107-0","volume":"53","author":"GD Anderson","year":"2014","unstructured":"Anderson GD, Hakimian S (2014) Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet 53(1):29\u201349","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"266_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0378-4347(96)00088-6","volume":"686","author":"F Bressolle","year":"1996","unstructured":"Bressolle F, Bromet-Petit M, Audran M (1996) Validation of liquid chromatographic and gas chromatographic methods. Applications to pharmacokinetics. J Chromatogr B Biomed Appl 686(1):3\u201310","journal-title":"J Chromatogr B Biomed Appl"},{"issue":"12","key":"266_CR4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/0003088-200847120-00002","volume":"47","author":"P Bring","year":"2008","unstructured":"Bring P, Ensom MH (2008) Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. Clin Pharmacokinet 47(12):767\u2013778","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"266_CR5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","volume":"24","author":"G Flesch","year":"2004","unstructured":"Flesch G (2004) Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 24(4):185\u2013203","journal-title":"Clin Drug Investig"},{"issue":"11","key":"266_CR6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5414\/CPP40524","volume":"40","author":"G Flesch","year":"2002","unstructured":"Flesch G, Tudor D, Souppart C, D\u2019Souza J, Hossain M (2002) Oxcarbazepine final market image tablet formulation bioequivalence study after single administration an at steady state in healthy subjects. Int J Clin Pharmacol Ther 40(11):524\u2013532","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"266_CR7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.109.030593","volume":"39","author":"G Flesch","year":"2011","unstructured":"Flesch G, Czendlik C, Renard D, Lloyd P (2011) Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. Drug Metab Dispos 39(6):1103\u20131110","journal-title":"Drug Metab Dispos"},{"issue":"5\u20136","key":"266_CR8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/bdd.716","volume":"31","author":"A Fortuna","year":"2010","unstructured":"Fortuna A, Alves G, Falc\u00e3o A, Soares-da-Silva P (2010) Binding of licarbazepine enantiomers to mouse and human plasma proteins. Biopharm Drug Dispos 31(5\u20136):362\u2013366","journal-title":"Biopharm Drug Dispos"},{"issue":"21","key":"266_CR9","first-page":"209","volume":"3","author":"GX Hu","year":"2005","unstructured":"Hu GX, Qiu XJ, Zhou HY (2005) Determination of active metabolite of oxcarbazepine by RP-HPLC and study of its pharmacokinetics in Chinese healthy volunteers. Zhongguo Lin Chuang Yao Li Xue Za Zhi 3(21):209\u2013212","journal-title":"Zhongguo Lin Chuang Yao Li Xue Za Zhi"},{"issue":"3","key":"266_CR10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007691-200306000-00016","volume":"25","author":"SI Johannessen","year":"2003","unstructured":"Johannessen SI, Battino D, Berry DJ, Bialer M, Kr\u00e4mer G, Tomson T, Patsalos PN (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 25(3):347\u2013363","journal-title":"Ther Drug Monit"},{"issue":"1","key":"266_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/chromsci\/44.1.45","volume":"44","author":"JM Juenke","year":"2006","unstructured":"Juenke JM, Brown PI, Urry FM, McMillin GA (2006) Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC\u2013UV. J Chromatogr Sci 44(1):45\u201348","journal-title":"J Chromatogr Sci"},{"issue":"1","key":"266_CR12","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1111\/j.1528-1167.2011.03318.x","volume":"53","author":"DW Kim","year":"2012","unstructured":"Kim DW, Gu N, Jang IJ, Chu K, Yu KS, Cho JY, Yoon SH, Kim HS, Oh J, Lee SK (2012) Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. Epilepsia 53(1):e9\u2013e12","journal-title":"Epilepsia"},{"issue":"9457","key":"266_CR13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)70238-5","volume":"365","author":"N Lameire","year":"2005","unstructured":"Lameire N, Van Biesen W, Vanholder R (2005) Acute renal failure. Lancet 365(9457):417\u2013430","journal-title":"Lancet"},{"issue":"3","key":"266_CR14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CPP46119","volume":"46","author":"J Maia","year":"2008","unstructured":"Maia J, Almeida L, Falc\u00e3o A, Soares E, Mota F, Potgieter MA, Potgieter JH, Soares-da-Silva P (2008) Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 46(3):119\u2013130","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"266_CR15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","volume":"42","author":"TW May","year":"2003","unstructured":"May TW, Korn-Merker E, Rambeck B (2003) Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 42(12):1023\u20131042","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"266_CR16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","volume":"41","author":"B Meibohm","year":"2002","unstructured":"Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41(5):329\u2013342","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"266_CR17","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","volume":"42","author":"HM Neels","year":"2004","unstructured":"Neels HM, Sierens AC, Naelaerts K, Scharp\u00e9 SL, Hatfield GM, Lambert WE (2004) Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42(11):1228\u20131255","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"266_CR18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.pediatrneurol.2005.05.011","volume":"33","author":"RS Northam","year":"2005","unstructured":"Northam RS, Hernandez AW, Litzinger MJ, Minecan DN, Glauser TA, Mangat S, Zheng C, Souppart C, Sturm Y (2005) Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol 33(5):337\u2013344","journal-title":"Pediatr Neurol"},{"issue":"1","key":"266_CR19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2012.03595.x","volume":"54","author":"T Nunes","year":"2013","unstructured":"Nunes T, Rocha JF, Falc\u00e3o A, Almeida L, Soares-da-Silva P (2013) Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate andoxcarbazepine in healthy volunteers. Epilepsia 54(1):108\u2013116","journal-title":"Epilepsia"},{"issue":"1","key":"266_CR20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/WNF.0b013e31824150a5","volume":"35","author":"KJ Park","year":"2012","unstructured":"Park KJ, Kim JR, Joo EY, Seo DW, Hong SB, Ko JW, Kim SR, Huh W, Lee SY (2012) Drug interaction and pharmacokinetic modeling of oxcarbazepine in Korean patients with epilepsy. Clin Neuropharmacol 35(1):40\u201344","journal-title":"Clin Neuropharmacol"},{"key":"266_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2014.05.011","author":"E Perucca","year":"2014","unstructured":"Perucca E, Battino D, Tomson T (2014) Gender issues in antiepileptic drug treatment. Neurobiol Dis. doi: 10.1016\/j.nbd.2014.05.011","journal-title":"Neurobiol Dis"},{"issue":"2","key":"266_CR22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00194967","volume":"47","author":"MC Rouan","year":"1994","unstructured":"Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, Kourilsky O, Hillion D, Aldigier JC, Jungers P (1994) The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 47(2):161\u2013167","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"266_CR23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.yebeh.2013.07.016","volume":"29","author":"I Wegner","year":"2013","unstructured":"Wegner I, Wilhelm AJ, Sander JW, Lindhout D (2013) The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav 29(1):217\u2013221","journal-title":"Epilepsy Behav"}],"updated-by":[{"DOI":"10.1007\/s13318-016-0379-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000}}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-015-0266-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-015-0266-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-015-0266-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T09:39:41Z","timestamp":1717753181000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-015-0266-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,21]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["266"],"URL":"https:\/\/doi.org\/10.1007\/s13318-015-0266-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,21]]}}}